drugset
drugset / Trial / NCT02767752

Gemcitabine and Capecitabine With or Without T-ChOS as Adjuvant Therapy for Patients With Resected Pancreatic Cancer

NCT02767752 ↗

Phase 2 Terminated 21 enrolled Herlev Hospital GENIS · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a single center, randomized, double-blind, placebo-controlled phase II trial that will compare the efficacy of T-ChOS in combination with gemcitabine to gemcitabine alone as adjuvant treatment for 6 months in patients with surgically resected pancreatic adenocarcinoma.

Timeline

Start
2016-11
Primary completion
2018-07
Completion
2018-07

Outcome

Outcome not reported

Stopped (Enrollment): “Poor accrual and change of SOC (FOLFIRINOX in adjuvant setting)”

Drugs

EvaluationDrugModalityDoseRoute
Background Capecitabine Small molecule 1660 mg/m2 Oral
Background Gemcitabine Small molecule 1000 mg/m2 Intravenous

Indications

pancreatic adenocarcinoma